BISOPROLOL MONOFUMARATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H31NO4.C4H4O4
Molecular Weight	441.5152
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1

InChI

InChIKey=RZPZLFIUFMNCLY-WLHGVMLRSA-N

InChI=1S/C18H31NO4.C4H4O4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4;5-3(6)1-2-4(7)8/h5-8,14-15,17,19-20H,9-13H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020186s027s028lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.healthline.com/drugs/bisoprolol/oral-tablet#Highlights1 https://www.drugs.com/ppa/bisoprolol.html http://pharm-sci.tbzmed.ac.ir/Drug-Information/Integrative%20Medicine%20Professional%20Access/ProfDrugs/Bisoprololpd.html http://www.drugbank.ca/drugs/DB00612 https://en.wikipedia.org/wiki/Bisoprolol

Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020186s027s028lbl.pdf	Blocker 537	8.8 nM [IC50]
Cytochrome P450 2D6 61 Target ID: CHEMBL289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9523980	Substrate 661
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9523980	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020186s027s028lbl.pdf	Primary		Approved 8429	ZIAC Approved Use BISOPROLOL FUMARATE is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents. Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
52 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
40.37 ng/mL DRUG LABEL https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
661 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
609.8 ng × h/mL DRUG LABEL https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.07 h DRUG LABEL https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
70% DRUG LABEL https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BISOPROLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg single, oral Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	Other AEs: Dizziness, Tiredness... Other AEs: Dizziness (2 patients) Tiredness (1 patient) Shortness of breath (1 patient) Faintness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/
10 mg 1 times / day steady, oral (max) Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10023943/	unhealthy, adult n = 1327 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: unknown Population Size: 1327 Sources: https://pubmed.ncbi.nlm.nih.gov/10023943/	Sources: https://pubmed.ncbi.nlm.nih.gov/10023943/
5 mg 1 times / day steady, intravenous (max) Highest studied dose Dose: 5 mg, 1 times / day Route: intravenous Route: steady Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11527129/	unhealthy, adult n = 37 Health Status: unhealthy Condition: myocardial infarction Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/11527129/	Sources: https://pubmed.ncbi.nlm.nih.gov/11527129/
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Other AEs: Sweating increased, Arthralgia... Other AEs: Sweating increased (0.7%) Arthralgia (2.2%) Dizziness (2.9%) Headache (8.8%) Hypoaesthesia (1.1%) Dry mouth (0.7%) Bradycardia (0.4%) Insomnia (1.5%) Diarrhea (2.6%) Nausea (1.5%) Vomiting (1.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Disc. AE: Bradycardia, Fatigue... AEs leading to discontinuation/dose reduction: Bradycardia (< 1%) Fatigue (< 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (10.9%) Hypoaesthesia (1.5%) Sweating increased (1%) Arthralgia (2.7%) Dizziness (3.5%) Dry mouth (1.3%) Bradycardia (0.5%) Insomnia (2.5%) Depression (0.2%) Diarrhea (3.5%) Nausea (2.2%) Vomiting (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Disc. AE: Bradycardia, Fatigue... AEs leading to discontinuation/dose reduction: Bradycardia (< 1%) Fatigue (< 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 OCT2 647 OCT1 512 OCT3 150 OCTN1 29 OCTN2 66	P-gp 1537

Drug as perpetrator

Target	Modality	Activity
OCT3 150	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21641380/	no
OCTN1 29	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21641380/	no
OCTN2 71	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21641380/	no
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19740083/	yes [IC50 2.4 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21641380/	yes
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16671962/	yes

Drug as victim

Target	Modality	Activity
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9523980/	yes
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9523980/	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18974611/ \| https://pubmed.ncbi.nlm.nih.gov/16671962/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3127	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3127
ChemicalBook	CB03118896	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB03118896
ChemicalBook	CB13118893	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB13118893
ChemicalBook	CB33118897	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB33118897
ChemicalBook	CB73118895	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB73118895
ChemicalBook	CB83118892	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB83118892
MolPort	MolPort-003-666-876	https://www.molport.com/shop/molecule-link/MolPort-003-666-876
MolPort	MolPort-005-937-320	https://www.molport.com/shop/molecule-link/MolPort-005-937-320
eMolecules	901481	https://www.emolecules.com/cgi-bin/more?vid=901481

PubMed

Title	Date	PubMed
Prevention of experimental autoimmune cardiomyopathy in rabbits by receptor blockers.	2001	11908781
Beta-blockers in heart failure.	2001	11725388
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.	2001	11700777
Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2).	2001 Dec	11717602
Bisoprolol improves survival in rats with heart failure.	2001 Oct	11811360
Chiral separation of beta-blockers after derivatization with (-)-alphamethoxy-alpha-(trifluoromethyl)phenylacetyl chloride by gas chromatography.	2001 Oct	11693539
Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.	2001 Sep	11855665
[Differential therapy with beta blockers. What is their value, what are the risks?].	2001 Sep 27	11680926
Bisoprolol: a review of its use in chronic heart failure.	2002	12466013
Optimising the use of beta-blockers in older patients with heart failure.	2002	12381236
[The effect of aspirin on rheological properties of erythrocytes in essential hypertension].	2002	12152252
[Comparison beta-blockers and their relevance to pharmacologic therapy of cardiovascular diseases].	2002	11878202
Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging.	2002 Apr	11923805
Maintainance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation.	2002 Apr	11922651
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.	2002 Apr	11910315
Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats.	2002 Apr	11907159
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).	2002 Apr 2	11927527
Beta-blockers work as well in women as in men.	2002 Apr 5	12452171
[Hormonal hyperactivity in heart failure. Differences in beta blockers].	2002 Aug	12229258
[Pharmacology of beta blockers and their significance for therapy of hypertension].	2002 Aug	12229254
Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems.	2002 Aug	12171563
Current research on carvedilol in heart failure.	2002 Aug	12166050
Beta blockers in older persons with heart failure: tolerability and impact on quality of life.	2002 Dec	12433890
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.	2002 Feb	11996196
Fixed low-dose combination in first-line treatment of hypertension.	2002 Feb	11996195
Transoesophageal Doppler echocardiography provided important parameters in patients with dilated cardiomyopathy during bisoprolol therapy.	2002 Feb	11918138
[New and old beta-blockers in the treatment of heart failure].	2002 Feb	11887345
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.	2002 Feb	11835035
[Cost-effectiveness of bisoprolol in chronic heart failure].	2002 Feb 14	11887711
beta-Blocker therapy in heart failure: scientific review.	2002 Feb 20	11851582
[Beta blockers for hypertension. No negative influence on insulin resistance].	2002 Feb 21	11910826
Perindopril reverses myocyte remodeling in the hypertensive heart.	2002 Jan	11924731
Inappropriate tachycardia detection by a biventricular implantable cardioverter defibrillator.	2002 Jan	11877928
Can beta blockers be safely initiated at home in patients with heart failure?	2002 Jan	11834774
Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium.	2002 Jan	11815381
[Therapy relevant differences in beta blockers and ACE inhibitors. Innovation or plagiarism?].	2002 Jan 17	11847884
Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China.	2002 Jul	12189112
Present and future pharmacotherapy for heart failure.	2002 Jul	12083991
[Heart failure. Only every fifth patient is properly treated?].	2002 Jun 20	12136677
Unique effects of carvedilol on noradrenaline release in the human heart.	2002 Mar	11959042
Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.	2002 Mar	11893365
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.	2002 Mar 1	11897766
Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases.	2002 May	12374905
Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial.	2002 May	12042891
Effect of beta(1)-selective adrenergic blockade on maximal blood lactate steady state in healthy men.	2002 May	12012078
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.	2002 Nov	12419934
Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension.	2002 Nov	12401122
Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats.	2002 Oct	12396304
[Beta blockers in heart failure. Start with low and slowly increase the dosage!].	2002 Sep 19	12395713
Storms of ventricular tachyarrhythmias associated with primary hyperparathyroidism in a patient with dilated cardiomyopathy.	2003 Jan	12468064

Patents

Sample Use Guides

In Vivo Use Guide

2.5 to 40 mg once-daily dose

Route of Administration: Oral

In Vitro Use Guide

Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test and in the mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43-1300 µg/mL.

Name

Type

Language

BISOPROLOL MONOFUMARATE

Common Name

English

2-PROPANOL, 1-(4-((2-(1-METHYLETHOXY)ETHOXY)METHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (2E)-2-BUTENEDIOATE (1:1) (SALT)

Systematic Name

English

2-PROPANOL, 1-(4-((2-(1-METHYLETHOXY)ETHOXY)METHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (E)-2-BUTENEDIOATE (1:1) (SALT)

Systematic Name

English

2-PROPANOL, 1-(4-((2-(1-METHYLETHOXY)ETHOXY)METHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (2E)-2-BUTENEDIOATE (1:1)

Systematic Name

English

Code System Code Type Description

CAS

105878-43-1

Created by admin on Sat Dec 16 01:40:48 GMT 2023 , Edited by admin on Sat Dec 16 01:40:48 GMT 2023

PRIMARY

PUBCHEM

6917733

Created by admin on Sat Dec 16 01:40:48 GMT 2023 , Edited by admin on Sat Dec 16 01:40:48 GMT 2023

PRIMARY

FDA UNII

U057CX04H0

Created by admin on Sat Dec 16 01:40:48 GMT 2023 , Edited by admin on Sat Dec 16 01:40:48 GMT 2023

PRIMARY

ACTIVE MOIETY


					Y41JS2NL6U

BISOPROLOL

SUBSTANCE RECORD


					U057CX04H0

BISOPROLOL MONOFUMARATE

AE	Significance	Dose	Population
Faintness	1 patient	10 mg single, oral Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/
Shortness of breath	1 patient	10 mg single, oral Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/
Tiredness	1 patient	10 mg single, oral Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/
Dizziness	2 patients	10 mg single, oral Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/	unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/2897298/
Bradycardia	0.4%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Dry mouth	0.7%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Sweating increased	0.7%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Hypoaesthesia	1.1%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Vomiting	1.1%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Insomnia	1.5%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Nausea	1.5%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Arthralgia	2.2%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Diarrhea	2.6%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Dizziness	2.9%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Headache	8.8%	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Bradycardia	< 1% Disc. AE	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Fatigue	< 1% Disc. AE	20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Depression	0.2%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Bradycardia	0.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Sweating increased	1%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Dry mouth	1.3%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Hypoaesthesia	1.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Vomiting	1.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Headache	10.9%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Nausea	2.2%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Insomnia	2.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Arthralgia	2.7%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Diarrhea	3.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Dizziness	3.5%	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Bradycardia	< 1% Disc. AE	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf
Fatigue	< 1% Disc. AE	40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator